Avastin (bevacizumab) may be a cancer medication that interferes with the expansion and unfold of cancer cellswithin the body.
Avastin is employed to treat a definite style of brain tumour, and sure varieties of cancers of the excretory organ, lung, colon, rectum, cervix, ovary, or oviduct.
Avastin is additionally wont to treat cancer of the membrane lining the interior organs in your abdomen. it’ssometimes given as a part of a mixture of cancer medicines.
Submit your review
fever, chills, vomiting, and constipation;
swollen gums, painful mouth sores, pain when swallowing, skin sores, cold or flu symptoms, cough;
pain, swelling, warmth, or redness in one or both legs;
chest tightness or heavy feeling, pain spreading to the jaw or shoulder, nausea, sweating, general ill feeling;
missed menstrual periods;
signs of any skin infection--sudden redness, warmth, swelling, or oozing, or any skin wound or surgical incision that will not heal; or
dangerously high blood pressure--severe headache, blurred vision, pounding in your neck or ears, nosebleed, anxiety, confusion, severe chest pain, shortness of breath, irregular heartbeats.
Older adults may be more likely to have side effects from this medication.
Common Avastin side effects may include:
nosebleed, rectal bleeding;
increased blood pressure;
mild or occasional headache;
runny nose, sneezing;
dry or watery eyes;
dry or flaky skin;
changes in your sense of taste; or
Patients should continue treatment until disease progression or unacceptable toxicity. Metastatic Colorectal Cancer (mCRC) The recommended doses are 5 mg/kg or 10 mg/kg every 2 weeks when used in combination with intravenous 5-FU-based chemotherapy. Administer 5 mg/kg when used in combination with bolus-IFL. Administer 10 mg/kg when used in combination with FOLFOX4. Administer 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks when used in combination with a fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy regimen in patients who have progressed on a first-line Avastin-containing regimen. Non-Squamous Non-Small Cell Lung Cancer (NSCLC) The recommended dose is 15 mg/kg every 3 weeks in combination with carboplatin and paclitaxel. Glioblastoma The recommended dose is 10 mg/kg every 2 weeks. Metastatic Renal Cell Carcinoma (mRCC) The recommended dose is 10 mg/kg every 2 weeks in combination with interferon alfa. Cervical Cancer The recommended dose of Avastin is 15 mg/kg every 3 weeks as an intravenous infusion administered in combination with one of the following chemotherapy regimens: paclitaxel and cisplatin, or paclitaxel and topotecan. Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer The recommended dose is 10mg/kg every 2 weeks in combination with one of the following intravenous chemotherapy regimens: paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or 15 mg/kg every 3 weeks in combination with topotecan (every 3 weeks).